Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas

British Journal of Dermatology

Volumn 149, Issue 6, 2003, Pages 1095-1107

  Whittaker, S J ^a   Marsden, J R ^b   Spittle, M ^d   Russell Jones, R ^c  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b SELLY OAK HOSPITAL   (United Kingdom)

^c EALING HOSPITAL   (United Kingdom)

^d MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIBODY; ANTINEOPLASTIC AGENT; BEXAROTENE; CARMUSTINE; CD 5 ANTIBODY; CHLORAMBUCIL; CHLORMETHINE; CLADRIBINE; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; DOXORUBICIN; ETOPOSIDE; ETRETIN; FLUDARABINE; GAMMA INTERFERON; GEMCITABINE; INTERLEUKIN 12; METHOTREXATE; OINTMENT BASE; OKT 4; ONZAR; PELDESINE; PENTOSTATIN; PROTEIN P53; RETINOID; UNCLASSIFIED DRUG; VINCRISTINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CREAM; CUTANEOUS T CELL LYMPHOMA; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG RESPONSE; DRUG STABILITY; EDEMA; ELECTRON BEAM; EVIDENCE BASED MEDICINE; FEVER; GEL; HUMAN; HYPERLIPIDEMIA; HYPERSENSITIVITY REACTION; HYPOALBUMINEMIA; HYPOTENSION; HYPOTHYROIDISM; IMMUNE RESPONSE; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LYMPHOMATOID PAPULOSIS; METHODOLOGY; MORBIDITY; MYALGIA; MYCOSIS FUNGOIDES; NAUSEA AND VOMITING; PHOTOCHEMOTHERAPY; PHOTOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PUVA; REVIEW; SEX RATIO; SEZARY SYNDROME; SKIN ALLERGY; SKIN BIOPSY; SKIN CANCER; SKIN TUMOR; STEM CELL TRANSPLANTATION; TELANGIECTASIA; TH1 CELL; TOMOGRAPHY; TUMOR VOLUME; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOTHERAPY; LYMPHOMA, T-CELL, CUTANEOUS; MYCOSIS FUNGOIDES; PHOTOCHEMOTHERAPY; PHOTOPHERESIS; PROGNOSIS; RETINOIDS; SEZARY SYNDROME; SKIN NEOPLASMS; STEM CELL TRANSPLANTATION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0346095263     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2003.05698.x     Document Type: Review

References (67)

1. Willemze R, Kerl H, Sterry W et al. EORTC classification for primary cutaneous lymphomas: a proposal from the cutaneous lymphoma study group of the European Organisation for Research and Treatment of Cancer. Blood 1997; 90: 354-71.
2. Harris NL, Jaffe ES, Diebold J et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the clinical advisory committee meeting. Airlie House, Virginia, November 1997. Histopathology 2000; 36: 69-86.
3. Zackheim HS, Amin S, Kashani-Sabet M, McMillan A. Prognosis in cutaneous T-cell lymphoma by skin stage: long term survival in 489 patients. J Am Acad Dermatol 1999; 40: 418-25.
4. Van Doorn R, van Haselan CW, van Voorst Vader P et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000; 136: 504-10.
5. Kim YH, Jensen RA, Watanabe GI et al. Clinical stage IA (limited patch and plaque) mycosis fungoides. Arch Dermatol 1996; 132: 1309-13.
6. Kim YH, Chow S, Varghese A, Hoppe RT. Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. Arch Dermatol 1999; 135: 26-32.
7. de Coninck EC, Kim YH, Varghese A, Hoppe RT. Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. J Clin Oncol 2001; 19: 779-84.
8. Kim YH, Bishop K, Varghese A, Hoppe RT. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. Arch Dermatol 1995; 131: 1003-8.
9. Kaye FJ, Bunn PA Jr, Steinberg SM et al. A randomized trial comparing combination electron beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989; 321: 1748-90.
10. Whittaker SJ. Primary cutaneous T-cell lymphomas. In: Evidence-based Oncology (Williams H, Bigby M, Diepgen T et al., eds). London: BMJ Books, 2003; IX: 498-517.
11. Fraser-Andrews E, Woolford A, Russell Jones R, Whittaker SJ. Detection of a peripheral blood T-cell clone is an independent prognostic marker in mycosis fungoides. J Invest Dermatol 2000; 114: 117-21.
12. Scarisbrick JJ, Whittaker SJ, Evans A et al. Prognostic significance of tumour burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. Blood 2001; 97: 624-30.
13. Zackheim H, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. Arch Dermatol 1998; 134: 949-54.
14. Hoppe RT, Abel EA, Deneau DG, Price NM. Mycosis fungoides: management with topical nitrogen mustard. J Clin Oncol 1987; 5: 1796-803.
15. Ramsey DL, Halperin PS, Zeleniuch-Jacquotte A. Topical mechlorethamine therapy for early stage mycosis fungoides. J Am Acad Dermatol 1988; 19: 684-91.
16. Vonderheld EC, Tan ET, Kantor AF et al. Long term efficacy, curative potential and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T-cell lymphoma. J Am Acad Dermatol 1989; 20: 416-28.
17. Zackheim H, Epstein E, Crain W. Topical carmustine (BCNU) for cutaneous T-cell lymphoma: a 15-year experience in 143 patients. J Am Acad Dermatol 1990; 22: 802-10.
18. Breneman D, Duvic M, Kuzel T et al. Phase I and II trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol 2002; 138: 325-32.
19. Duvic M, Olsen E, Omura G et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2001; 44: 940-7.
20. Hermann JJ, Roenigk HH Jr. Hurria A et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long term follow-up. J Am Acad Dermntol 1995; 33: 234-42.
21. Roenigk HH Jr, Kuzel TM, Skoutelis AP et al. Photochemotherapy alone or combined with interferon alfa in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol 1990: 95 (Suppl.6): 198-205.
22. Honigsmann H, Brenner W, Rauschmeier W et al. Photochemotherapy for cutaneous T cell lymphoma. J Am Acad Dermatol 1984; 10: 238-45.
23. Ramsey DL, Lish KM, Yalowitz CB, Soter NA. Ultraviolet-B phototherapy for early stage cutaneous T-cell lymphoma. Arch Dermatol 1992; 128: 931-3.
24. Clark C, Dawe RS, Evans AT et al. Narrowband TL-01 phototherapy for patch stage mycosis fungoides. Arch Dermatol 2000; 136: 748-52.
25. Zane C, Leali C, Airo P et al. 'High dose' UVA1 therapy of widespread plaque-type, nodular and erythrodermic mycosis fungoides. J Am Acad Dermatol 2001; 44: 629-33.
26. Cotter GW, Baglan RJ, Wasserman TH, Mill W. Palliative radiation treatment of cutaneous mycosis fungoides: a dose response. Int J Radiat Oncol Biol Phys 1983; 9: 1477-80.
27. Jones GW, Hoppe RT, Glatstein E. Electron beam treatment for cutaneous T-cell lymphoma. Haematol Ontol Clin North Am 1995; 9: 1057-76.
28. Jones GW, Rosenthal D, Wilson LD. Total skin electron beam radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sezary syndrome). Cancer 1999; 85: 1985-95.
29. Hamminga B, Van Noordijk EM, Vloten WA. Treatment of mycosis fungoides: total skin electron beam irradiation vs topical mechlorethamine therapy. Arch Dermatol 1982; 118: 150-3.
30. Becker M, Hoppe RT, Knox SJ. Multiple courses of high dose total skin electron beam therapy in the management of mycosis fungoides. Int J Radiat Oncol Biol Phys 1995; 30: 1445-9.
31. Wilson L, Quiros PA, Kolenik SA et al. Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma. J Am Acad Dermatol 1996; 35: 69-73.
32. Jones GW, Kacinski BM, Wilson LD et al. Total skin electron beam radiation in the management of mycosis fungoides: consensus of the European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol 2002; 47: 364-70.
33. Bunn PA Jr, Ihde DC, Foon KA. The role of recombinant Interferon alpha-2a in the therapy of cutaneous T-cell lymphomas. Cancer 1986; 57: 1689-95.
34. Olsen EA, Rosen ST, Vollmer RT et al. Interferon alfa-2a in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1989; 20: 395-407.
35. Papa G, Tura S, Mandelli F et al. Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice? Br J Haematol 1991; 79: 48-51.
36. Dreno B, Claudy A, Meynadier J et al. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate. Br J Dermatol 1991; 125: 456-9.
37. Stadler R, Otte HG, Luger T et al. Prospective randomized multicentre clinical trial on the use of interferon alpha-2a plus acitretin versus interferon alpha-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998; 10: 3578-81.
38. Kuzel TM, Roenigk HH Jr, Samuelson E et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol 1995; 13: 257-63.
39. Rook AH, Wood GS, Yoo EK et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999; 94: 902-8.
40. Kaplan EH, Rosen ST, Norris DB et al. Phase II study of recombinant interferon gamma for treatment of cutaneous T-cell lymphoma. J Nat Cancer Inst 1990; 82: 208-12.
41. Cooper DL, Braverman IM, Sarris AH et al Cyclosporine treatment of refractory T-cell lymphomas. Cancer 1993; 71: 2335-41.
42. Bunn PA Jr, Hoffman SJ, Norris D et al. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). Ann Intern Med 1994; 121: 592-602.
43. Kurzrock R, Pilat S, Duvic M. Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol 1999; 17: 3117-21.
44. Dearden C, Matutes E, Catovsky D. Pentostatin treatment of cutaneous T-cell lymphoma. Oncology 2000; 14: 37-40.
45. Zackheim HS, Kashani-sabet M, Hwang ST. Low dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. J Am Acad Dermatol 1996; 34: 626-31.
46. Wollina U, Graefe T, Kaatz M. Pegylated doxorubicin for primary cutaneous T-cell lymphoma: a report on ten patients with follow-up. J Cancer Res Clin Oncol 2001; 127: 128-34.
47. Zinzani PL, Baliva G, Magagnoli M et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 2000; 18: 2603-6.
48. Olavarria E, Child F, Woolford A et al. T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement. Br J Haematol 2001; 114: 624-31.
49. Burt RK, Guitart J, Traynor A et al. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graft-versus-tumour effect. Bone Marrow Transplant 2000; 25: 111-13.
50. Molina A, Nademanee A, Arber DA, Forman SJ. Remission of refractory Sézary syndrome after bone marrow transplantation from a matched unrelated donor. Biol Blood Marrow Transplant 1999; 5: 400-4.
51. Knox S, Hoppe RT, Maloney D et al. Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood 1996; 87: 893-9.
52. Foss FM, Raubitscheck A, Mulshine JL et al. Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukaemia and lymphoma. Clin Cancer Res 1998; 4: 2691-700.
53. Lundin J, Osterborg A, Brittinger G et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol 1998; 16: 3257-63.
54. Lundin J, Hagberg H, Repp R et al. Phase II study of alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) in patients with advanced mycosis fungoides. Blood 2003; 101: 4267-72.
55. Olsen EA, Duvic M, Frankel A et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19: 376-88.
56. Duvic M, Martin AG, Kim Y, Olsen E. Worldwide Bexarotene Study Group. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early stage cutaneous T-cell lymphoma. Arch Dermatol 2001; 137: 581-93.
57. Duvic M, Hymes K, Heald P et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19: 2456-71.
58. Edelson R, Berger C, Gasparro F et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N Engl J Med 1987; 316: 297-303.
59. Heald P, Rook A, Perez M et al. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photopheresis. J Am Acad Dermatol 1992; 27: 427-33.
60. Fraser-Andrews E, Seed P, Whittaker S, Russell Jones R. Extra-corporeal photopheresis in Sézary syndrome: no significant effect in the survival of 44 patients with a peripheral blood T-cell clone. J Arch Dermatol 1998; 134: 1001-5.
61. Russell Jones R. Extracorporeal photopheresis in cutaneous T-cell lymphoma. Inconsistent data underline the need for randomized studies. Br J Dermatol 2000; 142: 16-21.
62. Evans AV, Wood BP, Scarisbrick JJ et al. Extracorporeal photopheresis in Sézary syndrome: hématologic parameters as predictors of response. Blood 2001; 98: 1298-301.
63. Bekkenk MW, van Geelen FA, van Voorst Vader PC et al. Primary and secondary cutaneous CD30+ lymphoproliferative disorders: a report from the Dutch cutaneous lymphoma group on the long term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000; 95: 3653-61.
64. Vonderheid EC, Sajjadian A, Kadin ME. Methotrexate is effective for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol 1996; 34: 470-81.
65. Van Doorn R, Scheffer E, Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis. Arch Dermatol 2002; 138: 191-8.
66. Griffiths CEM. The British Association of Dermatologists guidelines for the management of skin disease. Br J Dermatol 1999; 141: 396-7.
67. Cox NH, Williams HC. The British Association of Dermatologists Therapeutic Guidelines: can we AGREE? Br J Dermatol 2003; 148: 621-5.